Rohtak News Magazine

Metastatic Castration-Resistant Prostate Cancer Pipeline Assessment | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, Treatment Outlook, and Key Companies

 Breaking News
  • No posts were found

Metastatic Castration-Resistant Prostate Cancer Pipeline Assessment | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, Treatment Outlook, and Key Companies

August 23
23:37 2022
Metastatic Castration-Resistant Prostate Cancer Pipeline Assessment | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, nearly 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development expected to launch in the coming years.

Metastatic Castration-Resistant Prostate Cancer Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Castration-Resistant Prostate Cancer Market. 

The Metastatic Castration-Resistant Prostate Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

DelveInsight’s Report covers around 75+ products under different phases of clinical development like – 

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis

Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Castration-Resistant Prostate Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Metastatic Castration-Resistant Prostate Cancer Treatment.

  • Metastatic Castration-Resistant Prostate Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Metastatic Castration-Resistant Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Castration-Resistant Prostate Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight

Metastatic Castration-Resistant Prostate Cancer Therapeutics Landscape

There are approx. 75+ key companies which are developing the therapies Metastatic Castration-Resistant Prostate Cancer. Currently, Clovis Oncology has its Metastatic Castration-Resistant Prostate cancer drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Metastatic Castration-Resistant Prostate Cancer Market include:

• Surface Oncology

• Regeneron Pharmaceuticals

• Clovis Oncology

• AstraZeneca

• Veru Healthcare

• Hinova Pharmaceuticals

• Zenith Epigenetic

• Eli Lilly and Company

• Lantern Pharma

• Astellas Pharma/Seagen

• Pfizer

• Progenics Pharmaceutical

• Molecular Insight Pharmaceuticals

• Bayer

• Accutar Biotechnology Inc

• Hinova Pharmaceuticals

• Taiho Oncology, Inc.

• Forma Therapeutics, Inc.

• Dizal Pharmaceuticals

• Amgen

 

Metastatic Castration-Resistant Prostate Cancer – Emerging Drugs Under Different Phases of Clinical Development Include:

• SRF617: Surface Oncology

• Rucaparib: Clovis Oncology

• HP518: Hinova Pharmaceuticals

Download the sample report to learn more about the emerging therapies and key companies in the domain, at: https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight

 

 Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Metastatic Castration-Resistant Prostate Cancer Current Treatment Patterns

4. Metastatic Castration-Resistant Prostate Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Metastatic Castration-Resistant Prostate Cancer Late Stage Products (Phase-III)

7. Metastatic Castration-Resistant Prostate Cancer Mid-Stage Products (Phase-II)

8. Metastatic Castration-Resistant Prostate Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Metastatic Castration-Resistant Prostate Cancer Discontinued Products

13. Metastatic Castration-Resistant Prostate Cancer Product Profiles

14. Key Companies in the Metastatic Castration-Resistant Prostate Cancer Market

15. Key Products in the Metastatic Castration-Resistant Prostate Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Metastatic Castration-Resistant Prostate Cancer Unmet Needs

18. Metastatic Castration-Resistant Prostate Cancer Future Perspectives

19. Metastatic Castration-Resistant Prostate Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Crows Feet Market
“Crows Feet Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Crows Feet Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles